Erbitux FDA Approval History
FDA Approved: Yes (First approved February 12, 2004)
Brand name: Erbitux
Generic name: cetuximab
Dosage form: Injection
Company: ImClone Systems Incorporated
Treatment for: Colorectal Cancer, Head and Neck Cancer
Erbitux is epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of colorectal cancer and Head and Neck Cancer.
Development Timeline for Erbitux
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.